Neurokinin-1 receptor antagonists as novel antidepressants: trials and tribulations.
Based upon animal experiments and early clinical trials, neurokinin-1 receptor antagonists showed promise as novel antidepressants. Subsequently, however, more extensive clinical trials did not reveal evidence of efficacy in depression. The development of novel antidepressants will require a better understanding of the neural basis of antidepressant action in humans.
Hafizi
Sepehr
S
Neurosciences Building, University Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX, UK. sepehr.hafizi@psych.ox.ac.uk
Chandra
Prakash
P
Cowen
J
J
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000077608:Aprepitant; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy*; D015195:Drug Design; D006801:Humans; D023421:Models, Animal; D009025:Morpholines / Q000494:pharmacology* / Q000627:therapeutic use; D064729:Neurokinin-1 Receptor Antagonists; D013373:Substance P / Q000378:metabolism
D000928:Antidepressive Agents; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D000077608:Aprepitant; D013373:Substance P